Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 1 2

Status

Unknown 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1Plasma cell 1Genitourinary 1Gastrointestinal 1

Conditions

Prostatic Neoplasms 2Pancreatic Neoplasms 2Hypoxia 2Squamous Cell Carcinoma of Head and Neck 1Sarcoma 1Neoplasms, Plasma Cell 1Multiple Myeloma 1Carcinoma, Non-Small-Cell Lung 1

Interventions

TH 302 2pomalidomide 1inositol trispyrophosphate 1fluoromisonidazole 1fludarabine 1Tirapazamine 1Injections 1Ethiodized Oil 1Dexamethasone 1Cyclophosphamide 1Bortezomib 1Albumin-Bound Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Hypoxia × TH 302 × Clear all
NCT01522872 2016-06-02

Open-label Study of TH-302 and Dexamethasone With or Without Bortezomib or Pomalidomide in Subjects With Relapsed/Refractory Multiple Myeloma

Threshold Pharmaceuticals

Phase 1/2 Unknown
98 enrolled
Plasma cell

Hypoxia, Multiple Myeloma, Neoplasms, Plasma Cell

NCT00743379 2015-05-07

Dose-Escalation Study of TH-302 in Combination With A) Gemcitabine or B) Docetaxel or C) Pemetrexed to Treat Advanced Solid Tumors

Threshold Pharmaceuticals

Phase 1/2 Completed
71 enrolled
GastrointestinalGenitourinaryThoracic

Hypoxia, Carcinoma, Non-Small-Cell Lung, Pancreatic Neoplasms, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡